No Data
No Data
By August 9, 2024, the number of shareholders of Guangdong Jiaying Pharmaceutical (002198.SZ) was 22,367.
Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform on August 12 that as of August 9, 2024, according to the shareholder list issued by China Clearing, the number of shareholders of the company is 22,367.
The function and indication of Guangdong Jiaying Pharmaceutical (002198.SZ) Double-Throat Wind-Dispersing Granules are clearing heat and detoxifying, reducing swelling and benefiting the throat.
Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform on July 17 that the dual-purpose throat and wind dispersal produced by the company has the following functions: clearing heat and detoxifying, reducing swelling and soothing the throat. It is used for throat and mouth ulcers, gum swelling and pain, sinusitis, skin ulcers and other conditions caused by lung and stomach fever and toxicity.
As of July 10th, Guangdong Jiaying Pharmaceutical (002198.SZ) had a total of 22,404 shareholders.
On July 12th, Gelunhui reported that Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform that as of July 10, 2024, according to the shareholder roster issued by the China Securities Depository and Clearing Co., Ltd., the company has 22,404 shareholders.
Subdued Growth No Barrier To Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Price
Guangdong Jiaying Pharmaceutical: Guangdong Jiaying Pharmaceutical Co., Ltd.'s performance forecast for the first half of 2024.
Guangdong Jiaying Pharmaceutical (002198.SZ) issued a profit warning, with a projected net income of 46-58 million yuan, a year-on-year decrease of 68%-75%.
Jiaying Pharmaceutical (002198.SZ) announced its performance forecast for the first half of 2024, with an expected net income attributable to shareholders of the listed company of 4.6 million yuan to 5.8 million yuan, a year-on-year decrease of 68%-75%. After deducting non-recurring gains and losses, the net income is expected to be 0.8 million yuan to 1.2 million yuan, a year-on-year decrease of 93%-95%. In the first half of 2024, in response to the various challenges facing the company's operation, the company actively maintained the market sales of its leading products and worked to maintain market share. At the same time, the company made every effort to develop the market sales of potential exclusive varieties and relied on existing pharmaceutical products.
No Data